T-Cell Non-Hodgkin’s Lymphoma

Mogamulizumab Superior to Vorinostat in Cutaneous T Cell Lymphoma (12-13-2017)

Results were recently presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta from a international comparative clinical trail evaluating mogamulizumab in patients with previously treated cutaneous T-cell lymphoma... Continue Reading

Opdivo® Highly Effective for Some Patients with Lymphomas (08-16-2016)

The immunotherapeutic agent, Opdivo® (nivolumab), appears to provide long-lasting anti-cancer activity among some patients who have received extensive prior therapy for both B- and T-cell lymphomas. These results were recently published in the Journal... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (06-20-2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

FDA Grants Fast Track Designation to SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphoma (01-19-2015)

The U. S. Food and Drug Administration has granted Fast Track designation the synthetic hypericin (SGX301) development program for the first-line treatment of cutaneous T-cell lymphoma. Fast Track designation from the FDA is reserved for drugs that demonstrate... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (12-17-2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading

FDA Approves Beleodaq for Peripheral T-cell Lymphoma (07-24-2014)

The FDA announces its approval of Beleodaq (belinostat), a histone deacetylase inhibitor for treating peripheral T-cell lymphoma (PTCL), based on the results of the BELIEF study that found an overall response rate of nearly 26% among treated patients. PTCL... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (09-4-2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading

Targeted Agent Xalkori May Benefit Children with Anaplastic Lymphoma (05-23-2012)

The targeted agent Xalkori® (crizotinib) appears to drastically reduce the size of tumors in children with refractory anaplastic large cell lymphoma, according to the results of a phase I study that will be presented at the annual meeting of the American... Continue Reading

Lymphoma During Pregnancy Can Have Good Outcomes (03-14-2012)

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (05-23-2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

Next Page »